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Friesland, Izore, Leeuwarden, The NetherlandsAbstractThe introduction of molecular detection of infectious organisms has led to increased numbers of positive ﬁndings, as observed for pathogens
causing gastroenteritis (GE). However, because little is known about the prevalence of these pathogens in the healthy asymptomatic
population, the clinical value of these additional ﬁndings is unclear. A case–control study was carried out in a population of patients served by
general practitioners in the Netherlands. A total of 2710 fecal samples from case and matched control subjects were subjected to multiplex
real-time PCR for the 11 most common bacterial and four protozoal causes of GE. Of 1515 case samples, 818 (54%) were positive for one or
more target organisms. A total of 49% of the controls were positive. Higher positivity rates in cases compared to controls were observed for
Campylobacter spp., Salmonella spp., Clostridium difﬁcile, enteroinvasive Escherichia coli/Shigella spp., enterotoxigenic E. coli, enteroaggregative
E. coli, atypical enteropathogenic E. coli (EPEC), Cryptosporidium parvum/hominis, and Giardia lamblia. However, Dientamoeba fragilis and Shiga-like
toxigenic E. coli were detected signiﬁcantly less frequent in cases than in controls, while no difference in prevalence was found for typical EPEC
and enterohemorrhagic E. coli. The association between the presence of microorganisms and GE was the weakest in children aged 0 to 5
years. Higher relative loads in cases further support causality. This was seen for Campylobacter spp., Salmonella spp., enterotoxigenic E. coli, and
C. parvum/hominis, and for certain age categories of those infected with C. difﬁcile, enteroaggregative E. coli, and atypical EPEC. For D. fragilis and
Shiga-like toxigenic E. coli/enterohemorrhagic E. coli, pathogen loads were lower in cases. Application of molecular diagnostics in GE is rapid,
sensitive and speciﬁc, but results should be interpreted with care, using clinical and additional background information.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: e.s.bruijnesteijn@isala.nlIntroductionInfectious gastroenteritis (GE) is a common illness with an
incidence varying around 280 per 1000 person-years in the
Netherlands and 190 per 1000 person-years in England,Microbiol Infect 2015; 21: 592.e9–592.e19
nical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.cmi.2015.02.007depending on the exact deﬁnition of GE and on seasonal peaks
[1]. The burden for general practitioners (GP) is substantial; in
the Netherlands, eight of every 1000 persons will visit the GP
for gastrointestinal (GI) complaints, accounting for a total of
128 000 visits each year [2].
According to national guidelines, GPs may decide to send in
samples for microbiologic examination. In the past, these
samples were analysed mainly by antigen detection and/or
culture for bacterial causes of GE, and by microscopy detection
for parasitic causes. Nowadays, the detection of infectious
agents by molecular methods has become the routineEuropean Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
CMI Bruijnesteijn van Coppenraet et al. --- 592.e10diagnostic method in many medical microbiologic laboratories
in the Netherlands. It has replaced standard stool culture, an-
tigen detection and microscopy. In general, molecular detection
is rapid, sensitive and speciﬁc, and it enables universal applica-
tion for viruses, parasites and bacteria using only one sample.
Using real-time PCR, a signiﬁcant increase of Campylobacter
jejuni infections was found [3]. For Salmonella spp. and Shigella
spp./enteroinvasive Escherichia coli (EIEC), improved sensitivities
are also obtained [4]. For Yersinia enterocolytica, it is now
feasible to discern the pathogenic strains, whereas routine
culture cannot discriminate between pathogenic and
nonpathogenic types [5]. This also holds true for E. coli path-
otypes. For Clostridium difﬁcile, the detection of the toxin-coding
genes enable swift and more sensitive diagnosis compared to
the cumbersome cytotoxin neutralization test or the enzyme
immunoassay method [6].
Protozoa are more often diagnosed after implementation of
molecular detection [7]. Conventional diagnostics for protozoa
consists of microscopy, often with poor sensitivity. The quality
of detection relies greatly on the personal expertise and the
training of laboratory technicians. Furthermore, each of the
protozoa have speciﬁc difﬁculties in microscopic detection. For
instance, Cryptosporidium requires speciﬁc staining methods to be
visualized. As is true for bacteria, the sensitive molecular tech-
nique enables direct detection of pathogenic types: no longer is
Entamoeba dispar found; only Entamoeba histolytica is detected.
Also, intermittent shedding, as seen in giardiasis, is no longer
relevant in such a sensitive assay. Finally, ﬁxation of feces is no
longer necessary for the detection of Dientamoeba fragilis [7].
In addition to these practical advantages, application of mo-
lecular detection has led to discussions about the interpretation
and relevance of positive results. What is the value of detecting
a small bacterial load, the detection of “possibly pathogenic”
protozoa, or the detection of a virulence- or toxin-coding gene
instead of the toxin itself? Case–control studies can further
elucidate these issues. However, case–control studies, in which
a general population in a developed country is investigated for a
panel of GE agents using molecular methods, are lacking.
In this study, stool samples from subjects with and without
GI complaints were investigated using internally controlled
multiplexed real-time PCR. The positivity rates and the relative
detectable loads were analysed for the most common bacterial
and protozoan GI agents associated with GE.MethodsStudy population
The study population consisted of patients who visited the GP
for GI complaints and for whom microbiologic examination wasClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artirequested (cases), and a matched group of persons without GI
complaints (controls). Matching criteria were age group (<5,
5–20, 21–50 and >50 years of age), month of sample collec-
tion, sex and region. Case and control subjects were requested
to participate in the study by ﬁlling out a questionnaire and
providing a fresh stool sample. GI complaints were deﬁned as
diarrhoea and/or other abdominal discomfort for which an in-
fectious cause is likely, as assessed by the GP. Written approval
was obtained by the medical ethics review board, and data for
all samples were encoded to ensure anonymity according to the
board’s requirements. Control subjects were either recruited
by the GP (54%; consisting of patients visiting their GP for a
variety of non-GI medical problems, all ﬁtting criteria for an
immunocompetent patient) or were recruited by the labora-
tory and included healthy volunteers (46%). Control subjects
were excluded if they had experienced GI complaints within 4
weeks before sample collection. In total, 2802 stool samples of
case and control subjects were collected from August 2010
through December 2012.
Processing of stool samples
The stool samples from case and control subjects were pro-
cessed by the four participating laboratories, each from a
different representative region in the Netherlands, and were all
gathered from the regions in which the collaborating labora-
tories were located. Routine diagnostic analysis performed
prospectively for case samples was executed using local pro-
tocols. At each laboratory, handling and storage at −80°C of
aliquoted stool samples was performed identically. A central-
ized and independent analysis of all the case and control sam-
ples was executed in a blinded fashion by one of the
laboratories. The results of that analysis are presented here.
One aliquot of 100 μg frozen stool was used for nucleic acid
extraction. Brieﬂy, feces was suspended in 400 μL STAR buffer
(Roche), vigorously shaken on a Magnalyser (1 minute; Roche)
and pelleted (3 minutes, 13 000 rpm). A total of 100 μL of
supernatant was extracted on the MagnaPure96 (MP96; Roche)
using the DNA and Viral NA small volume kit, and total nucleic
acids were eluted in 100 μL.
Real-time PCR
Internally controlled multiplexed real-time PCR was performed
for the following microorganisms: Campylobacter spp., Salmo-
nella spp., pathogenic Yersinia enterocolitica, toxigenic Clostridium
difﬁcile, Shigella/EIEC, enterohemorrhagic E. coli (EHEC), Shiga-
like toxigenic E. coli (STEC), enterotoxigenic E. coli (ETEC),
enteroaggregative E. coli (EAEC), atypical and typical entero-
pathogenic E. coli, Entamoeba histolytica, Giardia lamblia, Crypto-
sporidium parvum/hominis and D. fragilis. PCR reactions were
performed in multiplex format with the internal controlropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 592.e9–592.e19
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592.e11 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIdetection included in each reaction mix. Bovine serum albumin
(20 mg/mL; Invitrogen, The Netherlands) was added to 15 μL
2 × TaqMan Fast Advance Master Mix (Life Technologies, USA).
Oligos diluted in Gibco molecular-grade water (Life Technol-
ogies) and 10 μL of DNA extract were added to the master mix
to form a total reaction volume of 30 μL. Detection was
executed with the ABI7500 real-time thermocycler (Life
Technologies) with the following program: 45 cycles of 95°C
for 15 seconds and 60°C for 60 seconds. Primers and probes
are listed in Table 1.
The performance of the multiplex assays regarding sensi-
tivity, speciﬁcity, reproducibility and stability was extensively
tested and conﬁrmed using analytical panels and clinical mate-
rials as well as international proﬁciency panels, if available.
The samples were checked by comparing the (prospective)
diagnostic results of the separate laboratories with the results
found by the centralized analysis described here. In case of
discrepant results, both the local prospective method as per-
formed by the participating laboratories and the retrospective
method described here were repeated using a new frozen
aliquot. In case of unresolved discrepancies, the sample was
excluded.
Statistical analysis
Statistical analysis was performed by SPSS software v18 (IBM,
USA). Dichotomous variables were tested by Fisher’s exact
test. Categorical variables with more than 2 categories were
tested by the chi-square test (SPSS) or Fisher’s exact test in
case of small groups (SISA). Continuous variables were tested
by the Mann-Whitney U test (exact in case of small groups). An
alpha value of 0.05 (two-tailed) was used as the signiﬁcance
level.en
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A total of 2802 samples were collected. Ninety-two samples
were excluded because of missing information, inconclusive
results or an insufﬁcient amount of material (Fig. 1). After
repeating the test for 14 samples, no samples were excluded as
a result of inhibition of the PCRs. A total of 1515 case and 1195
control subjects were included for analysis.
Matching criteria were all met, except for the month of
collection. Often a 1- to 2-week delay was observed between
collection of the case and of the control samples. The distri-
bution of the collected samples over the year is depicted in
Fig. 2, and age distribution is provided in Fig. 3.
Of 1221 case and 713 control subjects, a completely ﬁlled-
out questionnaire was present, and for an additional 293 caseClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 592.e9–592
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).e19
Campylobacter spp. (16S) ssu-rRNA 16S 10 Fcamp2 50-CAC GTG CTA CAA TGG CAT ATA CAA T-30 This study 13
10 CampR2 50-GG CTT CAT GCT CTC GAG TT-30 13
4.5 Pcamp3-MGB-FAM FAM-50-TAT GTC CCA GTT CGG ATT G-30-MGB This study 13
Yersinia enterocolytica Heat-stable toxin yst 10 Pr2a 50-AAT GCT GTC TTC ATT TGG AGC-30 14
10 Pr2c 50-ATC CCA ATC ACT ACT GAC TTC-30 14
4.5 Pyent2-TQ-NED NED-50-CAA GCA AGC TTG TGA TCC TCC G-30- BHQ1 14
Typical EPEC Bundle-forming pilin bfpA 10 bfpA_F1 50-ATC ACA CCT GCG GTA ACG G-30 15
10 bfpA_F2 50-TCA CAC CGG CGG TAA CG-30 15
10 bfpA_R 50-CGA RAA AGG TCT GTC TTT GAT TGA-30 15
4.5 bfpA_P NED-50-CAG CAA GCG CAA GCA CCA TTG C-30-BHQ1 15
EAEC Transcriptional regulator aggR 10 aggR_F 50-CAA TAA GGA AAA GRC TTG AGT CAG A-30 15
10 aggR_R1 50-TCA AGC AAC AGC AAT GCT GC-30 15
10 aggR_R2 50-TTA TCA AGC AAT AGC AAT GCT GCT-30 15
6.0 aggR_P VIC-50-CCT TAT GCA ATC AAG AAT-30-BHQ1 15
EAEC Dispersin translocator aat 10 pCVD432_F1 50-GGG CAG TAT ATA AAC AAC AAT CAA TGG-30 15
10 pCVD432_F2 50-GGG CAG TAT ATA AAC AAC AAC CAG TG-30 15
10 pCVD432_R 50-GCT TCA TAA GCC GAT AGA AGA TTA TAG G-30 15
1.5 pCVD432_P1 FAM-50-TCT CAT CTA TTA CAG ACA GCC-30-MGB 15
1.5 pCVD432_P2 FAM-50-CTC ATC TAT TAC AGA CAG CAA T-30-MGB 15
Clostridium difﬁcile Toxin A tcdA 10 FtcdA2 50-TTG TAT GGA TAG GTG GAG AAG TCA G-30 This study 16
10 CD-tcdA-R 50-AAT ATT ATA TTC TGC ATT AAT ATC AGC CCA T-30 16
3.0 MGB1 FAM-50-ATA TTG CTC TTG AAT ACA TAA A-30-MGB 16
3.0 MGB2 FAM-50-TAT TGT TCT TGA ATA CAT AAA AC-30-MGB 16
Entamoeba histolytica ssu-rRNA 18S 10 Ehd-239F 50-ATT GTC GTG GCA TCC TAA CTC A-30 17
10 Ehd-88R 50-GCG GAC GGC TCA TTA TAA CA-30 17
3.0 Histolytica-96T VIC-50-TCA TTG AAT GAA TTG GCC ATT T-30-MGB 17
Giardia lamblia ssu-rRNA 18S 3.7 Giardia-80F 50-GAC GGC TCA GGA CAA CGG TT-30 17
3.7 Giardia-127R 50-TTG CCA GCG GTG TCC G-30 17
3.0 Giardia-105T FAM-50-CCC GCG GCG GTC CCT GCT AG-30-BHQ 17
Cryptosporidium parvum/hominis DNAJ-ike protein 15 Fcpar 50-CTT TTT ACC AAT CAC AGA ATC ATC AGA-30 17
15 Rcpar 50-TGT GTT TGC CAA TGC ATA TGA A-30 17
3.0 Pcpar-MGB-Ned NED-50-TCG ACT GGT ATC CCT ATA A-30-MGB 17
Dientamoeba fragilis 5.8S-rRNA 5.8S 4.5 Df124F 50-CAA CGG ATG TCT TGG CTC TTT A-30 18
4.5 Df221R 50-TGC ATT CAA AGA TCG AAC TTA TCA C-30 18
3.0 Df172Trev MGB FAM-50-CAA TTC TAG CCG CTT AT-30-MGB 18
Internal control phocine herpesvirus Glycoprotein B gB 4.5/10 PhHV-267s 50-GGG CGA ATC ACA GAT TGA ATC-30 19
4.5/10 PhHV-337as 50-GCG GTT CCA AAC GTA CCA A-30 19
0.3/4.5 PhHV-305tq CY5–50-TTT TTA TGT GTC CGC CAC CAT CTG GAT C-30-BHQ2 19
EAEC, enteroaggregative E. coli; EHEC, enterohemorrhagic E. coli; EIEC, enteroinvasive E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; LT, heat-labile enterotoxin.
*(/Shigella): target gene is also present in several Shigella strains, but not encountered in the Shigella strains included in the speciﬁcity panel.
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FIG. 3. Age distribution of collected stool samples by age category.
FIG. 1. Inclusion of samples and available background information.
592.e13 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIand 481 control subjects, a partially ﬁlled-out questionnaire was
available (Table 2). A total of 1137 case subjects (93.1%) re-
ported having diarrhoea. Abdominal discomfort was the second
most common symptom (69.7%). Other complaints— including
the presence of mucus or blood in feces, vomiting and fe-
ver—were reported less frequently. Signiﬁcantly more cases
than controls reported recent travelling, antacid use and anti-
biotic use. Also, more household members with GE complaints
were reported by the case subjects than by control subjects
(Table 2).FIG. 2. Monthly distribution of collected stool samples from case and
matched control subjects.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licePositivity rates of GE-associated microorganisms
Of 1515 case samples, 818 (54%) were positive for one or
more target organisms. Of 1195 control samples, 584 (48.9%)
were positive (Table 3). A signiﬁcantly greater positivity rate in
case subjects compared to control subjects was observed for
Campylobacter spp., Salmonella spp., C. difﬁcile, Shigella/EIEC spp.,
ETEC, EAEC, atypical EPEC, C. parvum/hominis and G. lamblia. D.
fragilis, however, was detected signiﬁcantly less frequent in case
subjects than in control subjects (25.7% and 37.3%, respec-
tively; p < 0.0001). STEC was detected less often in case
samples (borderline signiﬁcance; p 0.067), whereas no signiﬁ-
cant difference in prevalence between case and control subjects
was observed for typical EPEC and EHEC (Table 3).
For most targets, the positivity rate in case versus control
subjects varied among age categories (Table 4). Frequently no
differences between case and control subjects were seen for
the youngest age categories (<5 and 5–20 years of age). For
example, control subjects’ carrying C. difﬁcile was particularly
high for children aged less than 5 years: 14.4% compared, to
10.5% of case subjects. In the older age categories, however,
asymptomatic carriership decreased. A similar phenomenon
was observed for G. lamblia, for which the age group 5 to 20
years had almost an identical portion of case subjects (7.7%) as
control subjects (7.2%) who were found to be positive,
whereas for the older age groups, more case subjects than
control subjects were found to be positive.
Y. enterocolytica was only detected twice, both in case sub-
jects. E. histolytica was not detected at all in this study.
In 216 case subjects (14.3%) and 107 control subjects (9.0%),
more than one target organism was detected. Because D. fragilis
was highly prevalent in this study, calculations were performed
a second time with D. fragilis eliminated from the equation. This
resulted in a total amount of 541 (35.7%) positive case samples,
of which 124 (8.2%) were positive for more than one organism.ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 592.e9–592.e19
nses/by-nc-nd/4.0/)
TABLE 2. Characteristics of study population and data retrieved from questionnaires
Characteristic
Data retrieved from number of questionnaires Case (n [ 1515) Control (n [ 1195)
p Cases matched (%)Case Control No. positive % No. positive %
Age 1515 1185
<5 years 152 10.4 104 8.8 NA 68.4
5–20 years 313 20.6 208 17.4 NA 66.5
21–50 years 557 36.8 445 37.6 NA 79.9
>50 years 493 32.2 428 36.1 NA 86.8
Sex 1515 1188
Male 651 43.0 518 43.3 NA 79.6
Female 864 57.0 678 56.7 NA 78.5
Recent travel abroad 1514 1194 226 14.9 72 6.0 0.000 NA
Household members with
gastroenteritis complaints
1282 713 221 14.6 43 3.6 0.000 NA
Antacid use 1501 1194 221 14.6 100 8.4 0.000 NA
Antibiotic use 1498 1192 99 6.5 29 2.4 0.000 NA
Diarrhoea 1221 NA 1137 93.1 NA NA NA NA
No diarrhoea 84 6.9 NA NA NA NA
<1 week diarrhoea 188 15.4 NA NA NA NA
1–2 weeks’ diarrhoea 313 25.6 NA NA NA NA
>2 weeks’ diarrhoea 636 52.1 NA NA NA NA
Abdominal pain/cramps 1355 NA 944 69.7 NA NA NA NA
Fever 1348 NA 185 13.7 NA NA NA NA
Vomiting 1346 NA 175 13.0 NA NA NA NA
Blood in stool 1345 NA 115 8.6 NA NA NA NA
Mucus in stool 1343 NA 302 22.5 NA NA NA NA
Partially ﬁlled out questionnaires are responsible for different counts of answers per question. Data regarding age and sex were retrieved from sample identiﬁers.
NA, not applicable.
TABLE 3. Overall positivity for the different target organisms
Organism
Case (n [ 1515) Control (n [ 1195)
p (case vs. control)No. positive % No. positive %
Campylobacter spp. 154 10.2 33 2.8 0.000
Salmonella spp. 28 1.8 4 0.3 0.000
Pathogenic Yersinia enterocolytica 2 0.1 0 — 0.507
Clostridium difﬁcile 64 4.2 21 1.8 0.000
Shigella/EIEC 14 0.9 0 — 0.000
EHEC 2 0.1 2 0.2 1.000
STEC 15 1.0 22 1.8 0.067
ETEC 48 3.2 8 0.7 0.000
EAEC 94 6.2 34 2.8 0.000
Atypical EPEC 144 9.5 84 7.0 0.022
Typical EPEC 10 0.7 10 0.8 0.655
Entamoeba histolytica 0 — 0 — —
Giardia lamblia 85 5.6 33 2.8 0.000
Cryptosporidium parvum/hominis 46 3.0 10 0.8 0.000
Dientamoeba fragilis 390 25.7 446 37.3 0.000
One or more detections 818 54.0 584 48.9 0.008
Negative 697 46.0 611 51.1
One or more detections excluding D. fragilis 541 35.7 230 19.2 0.000
Negative when excluding D. fragilis 974 64.3 965 80.8
1 target organism excluding D. fragilis 417 27.5 204 17.1 0.000
2 target organisms excluding D. fragilis 90 5.9 21 1.8
3 target organisms excluding D. fragilis 27 1.8 5 0.4
4 target organisms excluding D. fragilis 7 0.5 0 —
EAEC, enteroaggregative Escherichia coli (with aggR and/or aat); EHEC, enterohemorrhagic E. coli (with eaeA and stx1 and/or stx2); EIEC, enteroinvasive E. coli (with ipaH); EPEC,
enteropathogenic E. coli (typical with eaeA and bfpA, and atypical with only eaeA); ETEC, enterotoxigenic E. coli (with lt and/or st); STEC, Shiga-like toxigenic E. coli type (with stx1 and/
or stx2).
CMI Bruijnesteijn van Coppenraet et al. --- 592.e14For the control samples, the total amount of positive ﬁndings
was now 230 (19.2%); 26 samples (2.2%) showed multiple
target organisms (Tables 3 and 4).
Ct values
Translating the Ct-value ranges for the different target organ-
isms to relative loads, the organisms that showed signiﬁcantly
higher relative loads in cases than in controls wereClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artiCampylobacter spp., Salmonella spp., ETEC, typical EPEC,
C. parvum/hominis and G. lamblia (although statistical signiﬁcance
was not reached; p 0.084) (Fig. 4). For Salmonella spp., Ct values
of controls were never below 33. For other target organisms,
higher loads in case subjects were found only in speciﬁc age
categories: C. difﬁcile (age group 21–50), EAEC (age group
21–50) and atypical EPEC (age group <5). Frequently, similar
trends were seen but did not reach signiﬁcance or could not beropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 592.e9–592.e19
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 4. Positivity for all target organisms by age category
Organism
Case Control p (case vs. control)*
<5 (n [ 152)
5–20
(n [ 313)
21–50
(n [ 557)
>50
(n [ 493) <5 (n [ 104)
5–20
(n [ 208)
21–50
(n [ 445)
>50
(n [ 428)
<5 5–20 21–50 >50
No.
positive %
No.
positive %
No.
positive %
No.
positive %
No.
positive %
No.
positive %
No.
positive %
No.
positive %
Campylobacter spp. 7 4.6 28 8.9 60 10.8 59 12.0 0 — 6 2.9 14 3.1 13 3.0 0.044 0.006 0.000 0.000
Salmonella spp. 1 0.7 7 2.2 10 1.8 10 2.0 1 1.0 2 1.0 1 0.2 0 — 1.000 0.328 0.028 0.002
Pathogenic Yersinia enterocolytica 0 — 1 0.3 1 0.2 0 — 0 — 0 — 0 — 0 — — 1.000 1.000 —
Clostridium difﬁcile 16 10.5 10 3.2 15 2.7 23 4.7 15 14.4 2 1.0 4 0.9 0 — 0.436 0.136 0.059 0.000
Shigella/EIEC 1 0.7 2 0.6 7 1.3 4 0.8 0 — 0 — 0 — 0 — 1.000 0.519 0.019 0.128
EHEC 0 — 1 0.3 0 — 1 0.2 0 — 0 — 2 0.4 0 — — 1.000 0.197 1.000
STEC 1 and 2 0 — 2 0.6 8 1.4 5 1.0 1 1.0 2 1.0 11 2.5 8 1.9 0.406 0.653 0.252 0.402
ETEC 3 2.0 2 0.6 29 5.2 14 2.8 1 1.0 1 0.5 4 0.9 2 0.5 0.648 1.000 0.000 0.009
EAEC 11 7.2 12 3.8 39 7.0 32 6.5 5 4.8 4 1.9 17 3.8 7 1.6 0.601 0.301 0.037 0.000
Atypical EPEC 33 21.7 23 7.3 50 9.0 38 7.7 12 11.5 16 7.7 27 6.1 28 6.5 0.044 0.867 0.095 0.524
Typical EPEC 6 3.9 0 — 1 0.2 3 0.6 4 3.8 1 0.5 0 — 5 1.2 1.000 0.399 1.000 0.483
Entamoeba histolytica 0 — 0 — 0 — 0 — 0 — 0 — 0 — 0 — — — — —
Giardia lamblia 14 9.2 24 7.7 24 4.3 23 4.7 4 3.8 15 7.2 10 2.2 4 0.9 0.135 1.000 0.081 0.001
Cryptosporidium parvum/hominis 12 7.9 9 2.9 21 3.8 4 0.8 5 4.8 2 1.0 2 0.4 1 0.2 0.446 0.213 0.000 0.380
Dientamoeba fragilis 49 32.2 145 46.3 113 20.3 83 16.8 36 34.6 122 58.7 160 36.0 124 29.0 0.787 0.007 0.000 0.000
One or more detections 101 66.4 206 65.8 283 50.8 228 46.2 66 63.5 140 67.3 207 46.5 166 38.8 0.689 0.776 0.182 0.023
Negative 51 33.6 107 34.2 274 49.2 265 53.8 38 36.5 68 32.7 238 53.5 262 61.2
One or more detections excluding
D. fragilis
79 52.0 99 31.6 198 35.5 165 33.5 44 42.3 44 21.2 77 17.3 63 14.7 0.161 0.009 0.000 0.000
Negative when excluding D. fragilis 73 48.0 214 68.4 359 64.5 328 66.5 60 57.7 164 78.8 368 82.7 365 85.3
1 target organism excluding D. fragilis 59 38.8 82 26.2 149 26.8 127 25.8 40 38.5 38 18.8 65 14.6 59 13.8
2 target organisms excluding
D. fragilis
15 9.9 13 4.2 33 5.9 29 5.9 4 3.8 5 2.4 9 2.0 3 0.7 0.056 0.088 0.000 0.000
3 target organisms excluding
D. fragilis
5 3.3 3 1.0 14 2.5 5 1.0 0 — 1 0.5 3 0.7 1 0.2
4 target organisms excluding
D. fragilis
0 — 1 0.3 2 0.4 4 0.8 0 — 0 — 0 — 0 —
EAEC, enteroaggregative Escherichia coli (with aggR and/or aat); EHEC, enteroheamorrhagic E. coli (with eaeA and stx1 and/or stx2); EIEC, enteroinvasive E. coli (with ipaH); EPEC, enteropathogenic E. coli (typical with eaeA and bfpA, and atypical with
only eaeA); ETEC, enterotoxigenic E. coli (with lt and/or st); STEC, Shiga-like toxigenic E. coli type (with stx1 and/or stx2).
*Signiﬁcance (Fisher’s exact test) included for cases vs. controls per age category.
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FIG. 4. Distribution of Ct values in case versus control subjects per age category. Difference between case and control subjects is signiﬁcant at
*p < 0.05 and **p < 0.005.
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ﬁndings (Fig. 4). Interestingly, the lower prevalences of STEC
and D. fragilis (Table 3) were accompanied by signiﬁcantly lower
relative loads in case subjects compared to control subjects
(Fig. 4).DiscussionComparison of positivity rates of the normal patient population,
routinely tested in our laboratories, with those of the study
population revealed similar results, thus ruling out selection
bias (results not shown). Also, the occurrence of diarrhoea was
only 93.1% in the case population. The criteria for GE were
assessed by the GPs and therefore was in complete concor-
dance with the variability of stool samples that are routinely
processed in the participating laboratories.
In total, 54.0% of case subjects and 48.9% of control sub-
jects were positive for one or more target organisms.
Although all target organisms were expected to be more
prevalent in case subjects than in control subjects, no differ-
ence in occurrence was observed for typical EPEC and EHEC.
Remarkably, D. fragilis (p < 0.0001) and STEC (p 0.067) were
detected even less frequently in case subjects compared to
control subjects.
As a result of the high prevalence of D. fragilis in both case
(25.7%) and control (37.3%) subjects, as well as its questionable
pathogenic status, the total positivity rates were recalculated
without Dientamoeba: 35.7% total positivity was found for case
and 19.2% for control subjects. The reduction in positivity was
observed among all age categories. However, in the <5-year
category, the total asymptomatic positivity excluding D. fragilis
was still 42.3% (Table 4). The total detection yield excluding
D. fragilis for case subjects was also highest in the <5 age
category, at 52%. Therefore, the statistical signiﬁcant associa-
tion of a positive detection with clinical illness is smallest in
young children. The differences in detection rates between case
and control subjects are more evident in the two older age
categories, and therefore, causal relations between pathogen
and complaints are stronger in the age categories 21–50 years
and >50 years.
Few case–control studies have been published with com-
parable patient populations that investigated the occurrence of
a panel of GI-associated organisms. One study in Great Britain
used molecular detection methods on stored samples
(1993–1996) from a population that had been previously tested
using conventional methods [20]. The most important ﬁnding of
Amar and colleagues [20] was the increased amount of positive
detections both in case and control subjects for all target or-
ganisms that were included in the molecular reinvestigation.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceThe second comparable study (1996–1999) was from the
Netherlands and primarily used conventional methods [21].
Compared to control subjects, higher occurrences were found
in case subjects for Salmonella spp., Campylobacter spp., Cryp-
tosporidium and the viruses tested. Interestingly, the positivity
rates for most pathogens tested (excluding Shigella/EIEC,
C. parvum/hominis and D. fragilis) were in the same range as in
our study. One would expect to ﬁnd higher occurrences using
molecular techniques, as has been shown in other studies [4,5].
A possible explanation is that since the de Wit study [21] was
performed, the incidence of intestinal infections has decreased
as a result of increased hygienic measures and awareness in the
food industry and in the general population.
Furthermore, both Amar et al. [20] and de Wit et al. [21]
reported a high prevalence of target organisms in control
subjects, which seems to be in concordance with the results
presented here. In the study of de Wit et al., Dientamoeba was
observed at a nonsigniﬁcantly higher frequency in controls—a
ﬁnding that was clearly signiﬁcant in our study using molecular
techniques.
In addition to prevalence, our case–control study also pro-
vides data on relative pathogen loads. Pathogen load is pro-
posed to be a second informative factor to determine causality
[22]. If a higher prevalence and a higher relative load (lower Ct
values) in cases of GI complaints is expected to prove causality,
then this is true for Campylobacter spp., Salmonella spp., ETEC
and C. parvum/hominis. For C. difﬁcile, EAEC and atypical EPEC,
this was seen only in speciﬁc age categories. The opposite is
true for D. fragilis and STEC, in which both load and prevalence
were lower in case subjects (prevalence STEC was not
signiﬁcant).
C. difﬁcile exempliﬁes an intestinal pathogen with a higher
relative load in case subjects for those age categories in which
higher prevalences were found. In the youngest age categories,
the occurrence in control subjects was comparable to that in
case subjects, as were the differences in pathogen load. High
numbers of C. difﬁcile–positive detection in children without GI
complaints are known [23], while asymptomatic carriership
among the elderly seems much less frequent [24]. This corre-
lates with our ﬁndings, which found decreasing relative load
with age in control subjects together with increasing differences
in pathogen load between case and control subjects with age
(Fig. 4).
Neither increased prevalence nor increased pathogen load in
case subjects was seen for STEC. Nevertheless, this E. coli
pathotype may cause severe clinical disease and has been
identiﬁed in many GI (pseudo)outbreaks, most often related to
food [25]. However, even in highly pathogenic STEC lineages,
asymptomatic infection has been previously recognized [26].
Also, colonization of E. coli pathotypes in the large intestineropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 592.e9–592.e19
nses/by-nc-nd/4.0/)
CMI Bruijnesteijn van Coppenraet et al. --- 592.e18does not necessarily activate pathogenic properties, while
infestation of the small intestine does [22]. Hence, substantial
occurrences of E. coli pathotypes may have been expected in
control subjects. However, in our study population, we found
STEC (including EHEC) to be more prevalent in the control
group than in the case group (borderline signiﬁcance, p 0.067).
Also, the Ct value range in control samples was signiﬁcantly
lower compared to cases (p 0.003; when including EHEC, p
0.008). This was true for both stx1-and stx2-positive strains.
When these results are investigated in more detail and sub-
typing is performed, we hope to provide an explanation for the
lack of disease association that we observed. These ﬁndings
indicate that the molecular detection of stx1 and stx2 genes of
E. coli pathotypes does not directly point to disease causality.
Another striking detection rate was observed for D. fragilis.
Lower prevalences were found in case subjects. This was
observed in all age groups, although a statistical difference was
lacking in the youngest age category. Pathogen load was similar
for all age categories except for the group of subjects aged >50
years, where relative loads were lower in cases. Doubts still
exist about the pathogenic signiﬁcance of D. fragilis [27]. Many
publications report that D. fragilis is present in subjects with GI
complaints, but little is known about the true prevalence in the
healthy population [28]. Because cases arise from the healthy
population and are thus superimposed on the prevalence in the
healthy population, the prevalence of a pathogen will always be
higher in cases than in the healthy population. In our study, both
the lower prevalence in cases and the lack of differentiation in
median Ct values between case and control subjects do not
support pathogenicity. Moreover, Röser and colleagues [29]
described a randomized double-blind, placebo-controlled
treatment trial. Metronidazole signiﬁcantly reduced the posi-
tivity in D. fragilis– infected children, whereas clinical complaints
were unchanged and remained indistinguishable to the placebo-
treated group. However, clinical relevance of intestinal D. fragilis
infection cannot be ruled out completely and may still exist for
individual cases.
In conclusion, for Campylobacter spp., Salmonella spp., ETEC
and C. parvum/hominis, and for certain age categories of
C. difﬁcile, EAEC and atypical EPEC, increased prevalence and
pathogen load in cases clearly suggest causality. However,
because a large overlap in Ct value ranges exists for all target
organisms except for Salmonella spp., pathogen load is unreli-
able to determine disease causality in practical use. Positive
molecular detection results of STEC/EHEC or D. fragilis do not
directly point to causality. The results of this study emphasize
that detection of a GI pathogen must be accompanied by clinical
data, and preferably other background and diagnostic data to
have sufﬁcient clinical meaning. The advantages of molecular
detection in terms of enhanced sensitivity and speed is helpful inClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artidiagnosing microbiologic causes of GE, but positive ﬁndings
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